GDRX
GoodRx Holdings, Inc. NASDAQ Listed Sep 23, 2020$2.84
Mkt Cap $973.3M
52w Low $1.77
26.5% of range
52w High $5.81
50d MA $2.21
200d MA $3.12
P/E (TTM)
29.9x
EV/EBITDA
4.1x
P/B
1.5x
Debt/Equity
0.1x
ROE
4.9%
P/FCF
5.9x
RSI (14)
—
ATR (14)
—
Beta
1.47
50d MA
$2.21
200d MA
$3.12
Avg Volume
2.8M
GoodRx Holdings, Inc., through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States. It also offers other healthcare products and services, including subscriptions, pharma manufacturer solutions, and telehealth services. It serves pharmacy benefit managers that manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was incorporated in 2015 and is headquartered in Santa Monica, California.
2701 Olympic Boulevard · Santa Monica, CA 90404 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | AMC | 0.07 | 0.07 | +0.0% | 2.57 | -2.3% | +10.5% | — | — | — | — | — |
| Feb 25, 2026 | AMC | 0.09 | 0.09 | +0.0% | 2.45 | -18.8% | -18.8% | -6.0% | +16.0% | -4.6% | +5.3% | — |
| Nov 4, 2025 | AMC | 0.09 | 0.08 | -11.1% | 3.26 | +3.1% | +2.1% | -5.1% | -1.6% | -1.6% | -1.0% | — |
| Aug 6, 2025 | AMC | 0.10 | 0.09 | -10.0% | 4.34 | -7.8% | -20.0% | +0.0% | +0.3% | +0.6% | +1.7% | — |
| May 7, 2025 | AMC | 0.09 | 0.09 | +0.0% | 3.79 | +6.3% | +11.9% | +1.9% | +0.7% | -1.1% | -0.7% | — |
| Feb 27, 2025 | AMC | 0.10 | 0.09 | -10.0% | 4.98 | -2.0% | +0.0% | -2.6% | -3.7% | +5.8% | -6.1% | — |
| Nov 7, 2024 | AMC | 0.09 | 0.08 | -11.1% | 5.04 | +1.6% | -3.0% | +0.0% | -3.9% | -0.9% | -2.1% | — |
| Aug 8, 2024 | AMC | 0.09 | 0.08 | -11.1% | 7.01 | +5.3% | +2.9% | -6.0% | +1.3% | -0.3% | +1.0% | — |
| May 9, 2024 | AMC | 0.09 | 0.08 | -11.1% | 6.93 | -1.0% | -4.8% | +1.5% | -0.7% | +9.3% | +10.9% | — |
| Feb 29, 2024 | AMC | 0.08 | 0.08 | +0.0% | 7.79 | +6.8% | +7.2% | -3.2% | -5.8% | -0.5% | -0.4% | — |
| Nov 9, 2023 | AMC | 0.06 | 0.06 | +0.0% | 4.44 | +0.0% | +7.9% | -1.7% | +5.9% | +5.8% | -1.5% | — |
| Aug 9, 2023 | AMC | 0.06 | 0.07 | +16.7% | 7.94 | +5.8% | +3.9% | -4.1% | -5.1% | -1.7% | -1.9% | — |
| May 10, 2023 | AMC | 0.06 | 0.07 | +16.7% | 4.80 | -0.6% | +4.6% | +1.6% | +2.0% | -2.5% | +3.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 4 | Wells Fargo | Maintains | Overweight → Overweight | — | $2.07 | $2.08 | +0.5% | +5.3% | +5.0% | -0.4% | +3.1% | +2.1% |
| Mar 3 | Citigroup | Maintains | Buy → Buy | — | $2.17 | $2.09 | -3.7% | -4.6% | +5.3% | +5.0% | -0.4% | +3.1% |
| Mar 2 | Goldman Sachs | Maintains | Neutral → Neutral | — | $1.87 | $1.80 | -3.7% | +16.0% | -4.6% | +5.3% | +5.0% | -0.4% |
| Feb 27 | JP Morgan | Downgrade | Overweight → Neutral | — | $1.99 | $1.99 | +0.0% | -6.0% | +16.0% | -4.6% | +5.3% | +5.0% |
| Feb 27 | Mizuho | Maintains | Neutral → Neutral | — | $1.99 | $1.99 | +0.0% | -6.0% | +16.0% | -4.6% | +5.3% | +5.0% |
| Jan 22 | Jefferies | Downgrade | Buy → Hold | — | $2.58 | $2.50 | -3.1% | -0.4% | -0.4% | -1.6% | -7.5% | +0.4% |
| Jan 9 | Citigroup | Maintains | Buy → Buy | — | $2.79 | $2.78 | -0.4% | +0.4% | +2.9% | -0.7% | -3.8% | -2.5% |
| Dec 18 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $2.78 | $2.76 | -0.7% | -1.4% | +1.1% | -2.2% | +1.5% | +0.7% |
| Nov 11 | JP Morgan | Maintains | Overweight → Overweight | — | $3.06 | $3.04 | -0.7% | -1.0% | +1.0% | +0.3% | -3.3% | -4.0% |
| Nov 10 | TD Cowen | Maintains | Buy → Buy | — | $3.11 | $3.13 | +0.6% | -1.6% | -1.0% | +1.0% | +0.3% | -3.3% |
| Nov 6 | UBS | Maintains | Neutral → Neutral | — | $3.33 | $3.33 | +0.0% | -5.1% | -1.6% | -1.6% | -1.0% | +1.0% |
| Nov 6 | Mizuho | Maintains | Neutral → Neutral | — | $3.33 | $3.33 | +0.0% | -5.1% | -1.6% | -1.6% | -1.0% | +1.0% |
| Aug 11 | UBS | Maintains | Neutral → Neutral | — | $3.47 | $3.42 | -1.4% | +0.3% | +0.6% | +1.7% | -0.6% | +5.4% |
| May 13 | UBS | Maintains | Neutral → Neutral | — | $4.35 | $4.34 | -0.2% | -1.1% | -0.7% | -6.1% | -1.2% | -0.3% |
| May 9 | Goldman Sachs | Maintains | Neutral → Neutral | — | $4.24 | $4.21 | -0.7% | +1.9% | +0.7% | -1.1% | -0.7% | -6.1% |
| Apr 29 | Wells Fargo | Maintains | Overweight → Overweight | — | $4.63 | $4.64 | +0.2% | +0.6% | -0.6% | +0.2% | +0.9% | +0.2% |
| Apr 10 | Truist | Maintains | Hold → Hold | — | $4.69 | $4.56 | -2.8% | -7.9% | +2.3% | +1.6% | +0.0% | -0.9% |
| Feb 28 | Wells Fargo | Maintains | Overweight → Overweight | — | $4.98 | $4.88 | -2.0% | +0.0% | -2.6% | -3.7% | +5.8% | -6.1% |
| Jan 10 | Citigroup | Maintains | Buy → Buy | — | $4.28 | $4.25 | -0.7% | +6.3% | -7.3% | -1.7% | +4.8% | +1.6% |
| Jan 8 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $4.41 | $4.38 | -0.7% | -2.9% | +6.3% | -7.3% | -1.7% | +4.8% |
| Dec 17 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $4.59 | $4.64 | +1.1% | -2.8% | -2.0% | +2.7% | -1.1% | +1.8% |
| Nov 13 | Citigroup | Maintains | Buy → Buy | — | $4.70 | $4.67 | -0.6% | -0.9% | -2.1% | -9.0% | +2.9% | -0.7% |
| Nov 11 | Barclays | Maintains | Overweight → Overweight | — | $4.89 | $4.98 | +1.8% | +0.0% | -3.9% | -0.9% | -2.1% | -9.0% |
| Aug 16 | RBC Capital | Maintains | Outperform → Outperform | — | $6.92 | $6.86 | -0.9% | +3.6% | +3.9% | +2.3% | -1.7% | +0.9% |
| Aug 9 | UBS | Maintains | Neutral → Neutral | — | $7.01 | $7.38 | +5.3% | +2.9% | -6.0% | +1.3% | -0.3% | +1.0% |
| Aug 9 | Citigroup | Maintains | Buy → Buy | — | $7.01 | $7.38 | +5.3% | +2.9% | -6.0% | +1.3% | -0.3% | +1.0% |
| Jun 10 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $8.55 | $8.70 | +1.8% | +4.2% | -0.2% | -0.4% | -0.8% | -3.1% |
| May 23 | RBC Capital | Upgrade | Sector Perform → Outperform | — | $7.20 | $7.80 | +8.3% | +0.6% | -1.4% | +1.8% | -0.7% | +4.7% |
| May 20 | Barclays | Maintains | Overweight → Overweight | — | $7.48 | $7.49 | +0.1% | -4.7% | +0.4% | +0.6% | +0.6% | -1.4% |
| May 16 | TD Cowen | Maintains | Buy → Buy | — | $7.27 | $7.80 | +7.3% | +10.9% | -7.2% | -4.7% | +0.4% | +0.6% |
| May 16 | Raymond James | Upgrade | Market Perform → Outperform | — | $7.27 | $7.80 | +7.3% | +10.9% | -7.2% | -4.7% | +0.4% | +0.6% |
| Apr 10 | KeyBanc Capital Markets | Upgrade | Sector Weight → Overweight | — | $6.74 | $6.87 | +1.9% | +3.9% | -1.1% | -1.3% | -4.1% | -0.5% |
| Mar 25 | Wells Fargo | Upgrade | Equal Weight → Overweight | — | $6.58 | $7.60 | +15.5% | +7.4% | -0.1% | -0.7% | +1.3% | +0.0% |
| Mar 8 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $7.54 | $7.64 | +1.3% | -2.0% | -0.5% | -1.8% | -1.1% | -5.2% |
| Mar 1 | TD Cowen | Maintains | Outperform → Outperform | — | $7.79 | $8.32 | +6.8% | +7.2% | -3.2% | -5.8% | -0.5% | -0.4% |
| Mar 1 | Goldman Sachs | Maintains | Neutral → Neutral | — | $7.79 | $8.32 | +6.8% | +7.2% | -3.2% | -5.8% | -0.5% | -0.4% |
| Mar 1 | JP Morgan | Upgrade | Neutral → Overweight | — | $7.79 | $8.32 | +6.8% | +7.2% | -3.2% | -5.8% | -0.5% | -0.4% |
| Mar 1 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $7.79 | $8.32 | +6.8% | +7.2% | -3.2% | -5.8% | -0.5% | -0.4% |
| Mar 1 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $7.79 | $8.32 | +6.8% | +7.2% | -3.2% | -5.8% | -0.5% | -0.4% |
| Mar 1 | Truist | Maintains | Hold → Hold | — | $7.79 | $8.32 | +6.8% | +7.2% | -3.2% | -5.8% | -0.5% | -0.4% |
| Mar 1 | Barclays | Maintains | Overweight → Overweight | — | $7.79 | $8.32 | +6.8% | +7.2% | -3.2% | -5.8% | -0.5% | -0.4% |
| Mar 1 | UBS | Maintains | Neutral → Neutral | — | $7.79 | $8.32 | +6.8% | +7.2% | -3.2% | -5.8% | -0.5% | -0.4% |
| Jan 16 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $6.64 | $6.54 | -1.5% | -5.1% | +0.5% | +2.7% | -1.1% | +2.2% |
| Jan 12 | Truist | Maintains | Hold → Hold | — | $6.57 | $6.67 | +1.5% | +1.1% | -5.1% | +0.5% | +2.7% | -1.1% |
| Jan 2 | BofA Securities | Downgrade | Buy → Underperform | — | $6.70 | $6.13 | -8.5% | -16.1% | -4.4% | +6.1% | -3.7% | +2.0% |
| Nov 17 | JP Morgan | Maintains | Neutral → Neutral | — | $5.20 | $5.25 | +1.0% | +0.6% | +10.1% | -3.0% | +4.5% | +0.9% |
| Nov 13 | Goldman Sachs | Maintains | Neutral → Neutral | — | $4.79 | $4.75 | -0.8% | -1.7% | +5.9% | +5.8% | -1.5% | +0.6% |
| Nov 10 | Goldman Sachs | Maintains | Neutral → Neutral | — | $4.44 | $4.44 | +0.0% | +7.9% | -1.7% | +5.9% | +5.8% | -1.5% |
| Nov 10 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $4.44 | $4.44 | +0.0% | +7.9% | -1.7% | +5.9% | +5.8% | -1.5% |
| Nov 10 | Truist | Maintains | Hold → Hold | — | $4.44 | $4.44 | +0.0% | +7.9% | -1.7% | +5.9% | +5.8% | -1.5% |
No insider trades available.
8-K · 5.02
!!! Very High
GoodRx Holdings, Inc. -- 8-K 5.02: Executive Change
GoodRx appointed Thomas Chan as Chief Accounting Officer, strengthening its financial leadership and accounting oversight capabilities.
Apr 24
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
The departure of an executive at GoodRx signals potential uncertainty about strategic direction and could pressure the stock if the departing executive held critical operational or strategic responsibilities.
Apr 3
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
GoodRx's departure of an executive signals potential leadership instability and may indicate internal challenges, risking investor confidence and operational continuity during a critical period.
Mar 27
8-K · 4.01
!!! Very High
Unknown — 8-K 4.01: Auditor Change / Resignation
GoodRx's auditor resignation without dispute raises concerns about potential accounting issues or cost pressures, warranting closer examination of financial statements and governance before investing.
Mar 18
8-K · 5.02
!!! Very High
GoodRx Holdings, Inc. -- 8-K 5.02: Executive Change
GoodRx's executive departure increases investor uncertainty about leadership stability and strategic direction, potentially pressuring the stock until a replacement is announced and market confidence in continuity is restored.
Mar 6
8-K · 5.02
!!! Very High
GoodRx Holdings, Inc. -- 8-K 5.02: Executive Change
GoodRx Holdings' director Dipanjan Deb resigned, which may signal internal shifts in leadership but doesn't materially impact the company's operations or investor outlook.
Feb 27
8-K
GoodRx Holdings, Inc. -- 8-K Filing
GoodRx delivered 2025 results in line with guidance while Pharma Direct revenue exceeded expectations with over 40% year-over-year growth, demonstrating strength in its higher-margin business segment.
Feb 25
Data updated apr 25, 2026 10:58am
· Source: massive.com